US Peptide Science Research Team
July 7, 2026
The Medicare GLP-1 Bridge is a short-term demonstration program administered by the Centers for Medicare & Medicaid Services (CMS) that operates from July 1, 2026, through December 31, 2027. According to cms.gov, the program provides eligible Medicare Part D beneficiaries with access to certain glucagon-like peptide-1 (GLP-1) receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists for weight reduction and weight maintenance in combination with lifestyle modification.
The Bridge operates as a separate demonstration outside the standard Medicare Part D benefit structure. This distinction is critical for researchers and beneficiaries: the $245 net monthly cost is subsidized by participating manufacturers, beneficiaries pay only $50 out-of-pocket, and this copay does not count toward Part D cost-sharing thresholds, deductibles, or true out-of-pocket (TrOOP) costs.
Beneficiaries must meet specific clinical criteria at the time GLP-1 therapy is initiated—not at the time of prior authorization request. According to cms.gov, providers must attest that the beneficiary meets one of the following:
Critically, the clinical criteria must be met at the time therapy is initiated. For example, if a beneficiary initiated GLP-1 therapy in September 2024 with a BMI of 37 and currently has a BMI of 34 at the time of a July 2026 prior authorization request, the prescribing provider attests that the BMI ≥35 criterion was met at initiation—the current BMI does not disqualify the beneficiary.
As of April 6, 2026, cms.gov specifies three eligible GLP-1 drugs available through the Medicare GLP-1 Bridge:
Importantly, the single-dose vial and single-dose pen formulations of Zepbound® are not covered through the Bridge. Only the multi-dose KwikPen® is included.
These medications represent two distinct pharmacological classes relevant to researchers:
Research on tirzepatide's dual-agonist mechanism has shown superior weight loss compared to monotherapy in published clinical trials.
Access to GLP-1 medications through the Medicare GLP-1 Bridge requires a prior authorization (PA) request submitted by the prescribing provider. According to cms.gov, the following workflow applies:
Provider Submission: The prescribing provider submits a prior authorization request attesting that the beneficiary meets the clinical criteria and is prescribed the medication for weight reduction and weight maintenance in combination with ongoing lifestyle modification (structured nutrition and physical activity per FDA-approved label).
Central Processor Review: Humana, designated as the central processor, manages all prior authorization, claims adjudication, and pharmacy reimbursement. CMS has established a Bank Identification Number (BIN) and Processor Control Number (PCN) specific to Medicare GLP-1 Bridge claims.
Provider Eligibility: The prescribing provider does not need to be enrolled in Medicare to submit a prior authorization request or write a prescription. However, the provider must not be on the CMS Preclusion List for the drug to be coverable.
Beneficiary Enrollment Requirements: To qualify, the beneficiary must be enrolled in one of the following Medicare Part D plan types:
Ineligible Plan Types: Beneficiaries enrolled in private fee-for-service plans, section 1876 cost contract plans, section 1833 health care prepayment plans, PACE organizations, fallback plans, or religious fraternal benefit plans are not eligible unless also enrolled in a standalone PDP.
The Medicare GLP-1 Bridge operates with a distinct cost and payment architecture separate from standard Part D coverage:
Beneficiary Cost: $50 copay per monthly supply, regardless of the beneficiary's phase in the Part D benefit cycle (deductible, initial coverage, coverage gap, or catastrophic phase).
Cost-Sharing Exclusions: According to cms.gov, the $50 copay does not count toward:
Manufacturer Subsidy: Participating manufacturers provide eligible GLP-1 drugs at a net price of $245 per monthly supply. The pharmacy receives reimbursement at the wholesale acquisition cost (WAC) of the drug, less the $50 beneficiary copay, plus a dispensing fee and applicable sales tax.
Claims Processing: All claims must be submitted electronically using the NCPDP Telecommunication Standard. Paper claims and direct member reimbursements are not accepted. The Medicare GLP-1 Bridge is the primary payer and does not coordinate benefits with other payers; coupons and discount programs cannot be applied to Bridge claims.
Beneficiaries prescribed an eligible GLP-1 drug for a use that is coverable under the basic Medicare Part D benefit—regardless of whether the drug is on the plan's formulary—do not qualify for coverage under the Medicare GLP-1 Bridge. Examples include:
These uses fall under standard Part D coverage, and beneficiaries must pursue Part D formulary exception processes through their plan sponsors rather than the Bridge.
For researchers evaluating the clinical basis of GLP-1 therapy, understanding the pharmacodynamic mechanisms is relevant. GLP-1 receptor agonists act on central and peripheral GLP-1 receptors through multiple proposed pathways:
Dual GLP-1/GIP agonists such as tirzepatide add activation of GIP receptors, which may modulate energy expenditure and insulin sensitivity through distinct neural circuits. Published clinical trials comparing tirzepatide to semaglutide in adults with obesity and type 2 diabetes have reported differences in weight reduction outcomes between the dual-agonist and monotherapy approaches.
The Medicare GLP-1 Bridge represents a significant policy shift in access to these medications for older adults, reflecting growing clinical evidence for weight management benefits in this population.
The Medicare GLP-1 Bridge is nationwide and available in all U.S. states and territories beginning July 1, 2026. The demonstration period extends through December 31, 2027, providing approximately 18 months of data collection on GLP-1 utilization patterns to inform potential implementation of the broader BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model in Medicare Part D.
Researchers and beneficiaries should note critical differences between Bridge coverage and standard Part D:
| Aspect | Medicare GLP-1 Bridge | Standard Part D |
|---|---|---|
| Deductible | Does not apply | Applies |
| Copay | $50 flat (all phases) | Varies by phase |
| Copay counts toward TrOOP | No | Yes |
| Low-income subsidy | Does not apply | Applies |
| Benefit coordination | Primary payer, no coordination | Standard coordination |
| Prior authorization | Centralized (Humana) | Plan-specific |
| Formulary requirement | Not applicable | Applies |
The Medicare GLP-1 Bridge represents a time-limited policy intervention to expand access to medications for Medicare beneficiaries meeting specific clinical criteria. Researchers tracking GLP-1 utilization patterns, real-world effectiveness, and health outcomes in older populations will benefit from the standardized eligibility criteria and centralized claims data generated through this demonstration.
For providers and plan administrators, understanding the three-tiered eligibility structure, covered medications, and prior authorization timeline is essential for implementing these medications during the 18-month demonstration period. The distinction between Bridge coverage and standard Part D coverage—particularly regarding cost-sharing and deductible application—significantly affects the payment structure and may influence coverage decisions.
Key takeaways: